Oncofetal antigen/immature laminin receptor antibodies for diagnostic and clinical applications

Abstract

The present invention relates to antibodies against Oncofetal Antigen/immature Laminin receptor protein (OFA/iLRP) that can be used singly or in conjunction to detect or treat OFA/iLRP-related diseases. More specifically, the antibodies can be used for several purposes including: (i) detecting and measuring OFA/iLRP in different biofluids; and (ii) using OFA/iLRP with an antibody directed against the monomeric form and its associated diseases.

1 . A method of treating an OFA/iLRP positive cancer comprising administering an amount an antibody specific for OFA/iLRP to a subject with the OFA/iLRP positive cancer that is sufficient to treat the cancer, wherein the antibody specific for OFA/iLRP specifically binds to an epitope of OFA/iLRP, wherein the epitope is or lies within the amino acid sequence VTDPRADHQPLTE (SEQ ID NO:3), YRDPEEIEKEEQ (SEQ ID NO:4), or YRDPEEIEKEEQC (SEQ ID NO:9). 
     
     
         2 . A method according to  claim 1 , wherein the antibody is linked to a colloid having anti-cancer properties. 
     
     
         3 . A method according to  claim 1 , wherein the antibody is conjugated with a chemotherapeutic agent. 
     
     
         4 . A method according to  claim 1 , wherein the epitope is or lies within the amino acid sequence YRDPEEIEKEEQ (SEQ ID NO.:4). 
     
     
         5 . A method according to  claim 1 , wherein the epitope is or lies within the amino acid sequence YRDPEEIEKEEQC (SEQ ID NO.:9). 
     
     
         6 . A method of detecting an OFA/iLRP positive cancer in a subject comprising: (a) conjugating an antibody specific for OFA/iLRP to a signal generator; (b) administering the conjugated antibody to a subject; and (c) detecting the conjugated antibody using an x-ray, wherein the detection of OFA/iLRP on the x-ray is indicative of cancer, wherein the antibody specific for OFA/iLRP specifically binds to an epitope of OFA/iLRP, wherein the epitope is or lies within the amino acid sequence VTDPRADHQPLTE (SEQ ID NO:3), YRDPEEIEKEEQ (SEQ ID NO:4), or YRDPEEIEKEEQC (SEQ ID NO:9). 
     
     
         7 . A method according to  claim 6 , wherein the signal generator is a radio opaque dye. 
     
     
         8 . A method according to  claim 6 , wherein the signal generator is a gadolinium chelate. 
     
     
         9 . A method according to  claim 6 , wherein the signal generator is a radionuclide. 
     
     
         10 . A method according to  claim 6 , wherein the signal generator is a fluorochrome. 
     
     
         11 . A method according to  claim 6 , wherein the epitope is or lies within the amino acid sequence YRDPEEIEKEEQ (SEQ ID NO:4). 
     
     
         12 . A method according to  claim 6 , wherein the epitope is or lies within the amino acid sequence YRDPEEIEKEEQC (SEQ ID NO:9).